Pharma Focus America

Olon Group Completes Acquisition of GTP Bioways Group

Wednesday, July 03, 2024

GTP Bioways Group, a French Biotech CDMO, specializes in research and development (R&D) services, process development, and the manufacturing of monoclonal antibodies (mAbs), enzymes, proteins, nanodrugs, antibody-drug conjugates (ADCs), and fill-and-finish (F&F) services. It operates from multiple sites in France including Toulouse, Labege, Veyre-Monton, and Saint-Julien-en-Genevois, catering to biopharmaceutical companies across all stages from preclinical research to commercial production. The company utilizes advanced technologies and adheres strictly to high-quality standards and regulatory requirements, ensuring compliance through regular inspections.

Integrated with Olon Biotech, GTP Bioways enhances Olon's capabilities throughout the drug development lifecycle—from R&D and preclinical phases to full-scale industrial production. GTP Bioways excels in biologics manufacturing, ADCs using both mammalian and microbial fermentation technologies, nanodrug formulation, and analytical development including assays for host cell proteins (HCP) and immunoassays. The company's expertise spans various expression systems (mammalian, bacterial, yeast, insect cells) and a wide range of molecules (mAbs, enzymes, cytokines, fusion proteins), along with proficiency in bioconjugation and fill & finish processes. This comprehensive service platform supports drug discovery through early clinical phases (phase I and II trials).

Olon Group, known for its strategic growth and global market expansion, strategically acquired GTP Bioways Group to strengthen its CDMO capabilities in biotechnology, particularly in the field of ADCs and early-stage molecule development (preclinical, phase I, and II trials). As part of its growth strategy, Olon Group plans a significant investment of €25 million in a state-of-the-art containment facility dedicated to the production of Ultra High Potent Active Pharmaceutical Ingredients (APIs), crucial for the development of ADCs. This investment underscores Olon's commitment to expanding its technological offerings and seizing new opportunities in high-potential markets.

 

Source: globenewswire.com

Thermo Fisher Scientific - mRNA ServicesFuture Labs Live USA 2024World Vaccine Congress Europe 2024World Orphan Drug Congress 2024Advanced Therapies USA 2024World Orphan Drug Congress Europe 2024